-Aishila Kar, Amity University Kolkata
The Indian Council of Medical Research (ICMR) in partnership with Hyderabad-based vaccine maker Biological E, has developed a “highly purified antisera” which will be utilized in the prevention and treatment of Covid-19.
Antisera are blood sera that carry antibodies against a selected viral toxin or antigen and are introduced to assist within the treatment or prevention of the diseases related to that virus.
Such measures have earlier been used in medical science to check many viral and bacterial infections like Rabies, Hepatitis B, Vaccinia virus, Tetanus, Botulism, and Diphtheria.
While plasma found from Covid-19 patients could serve the same purpose, ICMR said the study of antibodies, their effectiveness, and concentration keep differ from patient to patient. These factors, therefore, make plasma an “unreliable” clinical device for patient management, it added.
The study provides hope for the potential of generating highly purified F(ab’)2 from equines against SARS-CoV-2 that can demonstrate consistent as well as effective neutralization activity. Further, an in-vivo test for the efficacy of this cost-effective product could pave the way for clinical evaluation. Besides, this may prove as an efficient alternative to already existing and cumbersome to collect- plasma for the treatment of COVID-19 patients.
Source- News; https://www.financialexpress.com/lifestyle/health/big-breakthrough-icmr-biological-e-ltd-develop-potential-treatment-for-covid-19/2096384/
Also read: Location of working memory
For more artilces visit: bioxone.in
Good one